Updated: March 26, 2026
What Is Juluca? Uses, Dosage, and What You Need to Know in 2026
Author
Peter Daggett

Summarize with AI
Juluca is a two-drug HIV regimen combining dolutegravir and rilpivirine in a single daily tablet. Here's everything patients need to know about what Juluca is, how to take it, and who it's for.
Juluca is a prescription HIV medication that changed how some patients think about antiretroviral therapy. Instead of the traditional three-drug HIV pill, Juluca achieves viral suppression with just two drugs in a single once-daily tablet. Here's everything you need to know about Juluca — what it is, who it's for, how to take it, and what makes it different.
What Is Juluca?
Juluca is the brand name for a fixed-dose combination tablet containing two antiretroviral drugs:
Dolutegravir 50 mg — an integrase strand transfer inhibitor (INSTI)
Rilpivirine 25 mg — a non-nucleoside reverse transcriptase inhibitor (NNRTI)
Together, these two drugs block two different enzymes that HIV needs to replicate inside the body. Juluca is manufactured by ViiV Healthcare (a GSK company), in collaboration with Janssen, and was first approved by the FDA on November 21, 2017. It was the first complete two-drug, single-pill, once-daily HIV regimen approved in the United States.
Who Is Juluca For?
Juluca is specifically approved for a well-defined group of HIV-positive adults. It is not for everyone living with HIV. To be eligible for Juluca, all of the following must be true:
You are an adult (18 years or older) with HIV-1 infection
You are virologically suppressed — meaning your HIV-1 RNA (viral load) is below 50 copies per milliliter of blood
You have been on a stable antiretroviral therapy regimen for at least 6 months
You have no history of antiretroviral treatment failure
You have no known resistance mutations to either dolutegravir or rilpivirine
Juluca is a switch regimen — it is used to simplify therapy for patients who are already doing well on a three-drug regimen. It is not used as initial therapy for newly diagnosed patients, and it is not approved for children under 18.
How to Take Juluca
Juluca dosing is straightforward, but one rule is non-negotiable:
One tablet, once daily, always with a full meal. A protein shake or meal replacement drink is not an adequate substitute.
Take Juluca at the same time every day to maintain consistent drug levels.
If you miss a dose, take it as soon as you remember (with food). If it's almost time for your next dose, skip the missed dose — do not double up.
Store in the original container at room temperature (68°F–77°F), protected from moisture.
The food requirement for Juluca exists because rilpivirine has significantly lower absorption when taken without food — potentially reducing it to levels that could allow the virus to replicate and become resistant.
What Makes Juluca Different from Other HIV Regimens?
Most HIV regimens include three drugs: typically two NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors) plus one drug from another class. Juluca uses only two drugs — no NRTI backbone. This is a significant distinction because NRTIs like tenofovir and abacavir are associated with long-term side effects including kidney toxicity and bone mineral density loss in some patients.
By eliminating the NRTI backbone, Juluca reduces exposure to these agents for patients who have already achieved suppression and want to simplify or protect long-term organ health. Clinical trials (SWORD-1 and SWORD-2) demonstrated that Juluca maintains viral suppression at rates comparable to three-drug regimens — 95% of participants remained suppressed at week 48.
Is Juluca a Controlled Substance?
No. Juluca is not a controlled substance and has no abuse potential. It does not have DEA scheduling, and there are no restrictions on prescription refills based on controlled substance regulations. However, it does require a prescription from a licensed healthcare provider — it is not available over the counter.
Is There a Generic Version of Juluca?
As of 2026, no generic version of Juluca has been approved by the FDA. Both dolutegravir (patented by ViiV Healthcare) and rilpivirine (patented by Janssen) remain under patent protection, and generic entry is not expected in the near term. This is a key driver of Juluca's high retail price of approximately $5,000 per month.
If you're having trouble affording Juluca, manufacturer savings programs and ADAP can reduce costs dramatically — read our guide on how to save money on Juluca. And if finding Juluca at a pharmacy is the problem, medfinder can help you locate it near you.
Frequently Asked Questions
Juluca (dolutegravir/rilpivirine) is used to treat HIV-1 infection in adults who are already virologically suppressed on another antiretroviral regimen. It is a complete two-drug, once-daily HIV treatment that replaces a prior three-drug regimen in eligible patients who have been stable for at least 6 months with no history of treatment failure.
No. Juluca is not approved for initial HIV therapy in treatment-naive patients. It is specifically indicated as a switch regimen for adults who are already virologically suppressed (viral load below 50 copies/mL) on another stable antiretroviral therapy for at least 6 months, with no history of treatment failure.
Juluca is a two-drug regimen (dolutegravir + rilpivirine) with no nucleoside/nucleotide backbone, while Biktarvy is a three-drug regimen (bictegravir + emtricitabine + tenofovir alafenamide). Juluca eliminates NRTI exposure, which may benefit patients concerned about tenofovir-related long-term kidney or bone effects. Biktarvy has no food requirement, while Juluca must always be taken with a meal. Both are once-daily single tablets.
Juluca is manufactured by ViiV Healthcare, a global HIV-focused pharmaceutical company majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders. The rilpivirine component was developed by Janssen (part of Johnson & Johnson). ViiV Healthcare distributes Juluca in the United States.
Juluca treats HIV-1 infection by suppressing the virus to undetectable levels in the blood. While Juluca cannot cure HIV or AIDS, maintaining an undetectable viral load with Juluca helps preserve immune function (CD4 count), prevents HIV-related opportunistic infections, and reduces the risk of transmitting HIV to others. People with advanced HIV (AIDS) may need more comprehensive treatment planning.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Juluca also looked for:
More about Juluca
35,524 have already found their meds with Medfinder.
Start your search today.





